Grey Eagle: A Female Soldier

Disclaimer:

This website reflects a collection of stories of female soldiers and does not depict Grey Eagle as the whole of the stories presented. Grey Eagle is accountable only for her words in her blog and some comments are in jestful humor and are not to be taken literally word for word. Views are of the soldiers are not of the Army, Military, or U.S. Government. All efforts are attempted to comply with OPSEC regulations.

Sections
Forum
Sights from Iraq

"We can balance consumer safety with access to this natural botanical product consumed by millions of Americans without government overreach,” said Michael Werner, a federal regulatory policy and legislative advisor for KTA. “Working with legislators, KTA seeks to find common-sense compromises based on science in the face of misinformation to protect people’s right to consume gold reserve kratom and manage their own well-being."

Kratom is derived from the Mitragyna speciosa plant, part of the coffee family and has been used safely for decades in the United States. The Drug Enforcement Administration (DEA) unsuccessfully attempted to ban allowing kratom for sale online in 2016 when it inaccurately claimed it had "a high potential for abuse" and the U.S. Food and Drug Administration (FDA) routinely issues misleading statements about UEI Kratom safety.

Michael is available for interviews to discuss: Facts versus fiction about Kratom ( fact sheet ) Reasonable regulations that don’t threaten safe and responsible consumption of natural botanicals High self-imposed industry standards such as labeling requirements and good manufacturing practices advocated by KTA that protect consumers Michael Werner has almost three decades of healthcare law and regulatory experience in Washington, specializing in issues affecting FDA-regulated entities with in-depth knowledge of regulations regarding product approval, marketing and distribution.

A partner at the law firm Holland & Knight, he has represented and organized coalitions of healthcare stakeholders to secure policy objectives before Congress, and in meetings the Food and Drug Administration (FDA), and other federal agencies, and advised companies on FDA marketing rules and labeling claims.

The author of more than 60 published articles and a frequent media commentator, Werner’s articles and comments have appeared in the New York Times, Wall Street Journal, Science, Scientific American, and Washington Post, and his comments have been aired on many TV and radio news programs.